Pelvic Morphology in Quiet Posture and Its Effect on Gait

March 12, 2025 updated by: Yunus Emre Kundakçı, Afyonkarahisar Health Sciences University

Evaluation of the Effect of Pelvic Morphology in Quiet Standing on Spatiotemporal Parameters and Pelvic Movements During Gait

Pelvic orientations observed in the pelvis during quiet standing position the standard orientation of the pelvis, causing pelvic tilt, pelvic obliquity and pelvic rotation. There is a need to understand the relationship between these orientation disorders and gait. This is because the orientation of the pelvis both in standard standing posture and during gait is an integral part of physiotherapy assessment due to the various problems associated with abnormal pelvic position, including musculoskeletal disorders of the lumbar spine, pelvis, hips and knees. The aim of this study was to describe the morphology of pelvic orientation during static standing posture in an asymptomatic young Turkish population aged 19 to 29 years and to examine the relationship between morphologic changes and changes in pelvic tilt, pelvic obliquity and pelvic rotation angles during gait.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

The pelvic bones are the key structures that connect the trunk to the lower extremities, support the body's weight and transfer the load to the lower extremities. The symmetrical orientation of the pelvis about the horizontal plane determines the morphology of the pelvis during static standing posture. When the symmetry of the pelvis is disturbed, its effect on gait parameters is unclear. In clinical practice, the pelvis functionally has 3 basic rotational movements during a gait activity. These are associated with upward (positive) or downward (negative) movement of the pelvis in the coronal plane; forward or backward movement in the sagittal plane; and internal (positive) or external (negative) movement in the horizontal plane. Although these angles are determined by the balance of muscle and ligament forces acting between the pelvis and adjacent segments, they can also be affected by changes in pelvic morphology. If the height of the iliac crest in the coronal plane is significantly different on the right and left, this indicates a pelvic oblique asymmetry. On the other hand, pelvic asymmetries can also be seen in the sagittal plane. Here, the pelvic tilt angles on the right and left are usually significantly different from each other. In the literature, morphologic analyses of the pelvis in static standing posture or dynamically during a gait activity have been performed separately. However, to our knowledge, there is no study on the extent to which pelvic asymmetries seen during gait are affected by the morphology of the pelvis in static standing posture. In this study, the pelvis of young adults aged 19-29 years will be evaluated in two stages. In the first stage, pelvic orientation (pelvic tilt, pelvic obliquity and pelvic rotation) will be measured during static standing using a PALM (palpation meter pelvic inclinometer) inclinometer and leg length will be measured using a tape measure. In the second stage, spatio-temporal parameters and pelvic parallels will be assessed during walking using a wearable inertial sensor. With the data obtained, it is aimed to classify the pelvic morphology of the participants as symmetrical and asymmetrical in the literature and to reveal the effects of pelvis types specific to this classification on the parameters during walking. The results of this study will accurately and precisely measure the orientation of the pelvis with objective tools under static and dynamic conditions, which may increase the reasoning skills and understanding of rehabilitation strategies to be developed for pathologies related to this region. In addition, this study will elucidate the effect of pelvic asymmetries on the kinetic and kinematics of the pelvis on gait quality.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
167

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey
      • Afyonkarahisar, Turkey
        • Afyonkarahisar Health Science University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The participants of the study will consist of young adults between the ages of 19-29 studying at the Faculty of Health Sciences and Atatürk Vocational School of Health Services.

Description

Inclusion Criteria:

  • 19 to 29 years old
  • Not having a confirmed health problem (The participant's use of acute or chronic medication that causes neuromusculoskeletal system disorder will be confirmed by asking)

Exclusion Criteria:

  • Syndromes related to the Central Nervous System and/or locomotor system that interfere with proper psychomotor development,
  • Disorders potentially causing postural pathologies: genetic syndromes, hormonal disorders, neuromuscular diseases, congenital locomotor system defects,
  • Participants with a body mass index over 30,
  • Those who did not give written informed consent to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Morphological evaluation of the pelvis
Time Frame: Baseline
A caliper-based inclinometer (PALM palpation meter pelvic inclinometer) will be used to assess pelvic morphology in the standing position. The PALM consists of an inclinometer and two caliper arms. The assessments involve positioning the two calipers of the PALM in contact with the two bony prominences and reading the angle. The iliac crest, anterior superior iliac spine and greater trochanter on each side of the pelvis respectively will be marked by the assessor as reference measurement points. The calipers of the inclinometer will be placed in the horizontal plane on the same reference points left and right. Thus, the following 3 angles between the inclinometer and the horizontal plane will be measured in degrees.
Baseline
Gait analysis
Time Frame: Baseline
Gait parameters (gait speed, cadence, double stride length, double stride duration, single support and double support periods, sway and stance phase durations) will be evaluated with the BTS G-Walk device with the 10 Meter Walk Test.
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Leg Length Measurement
Time Frame: Baseline
A standard clinical tape measure that allows 1 mm measurements will be used to measure leg length. Measurements will be taken in the supine position for the right and left extremities. The proximal end of the tape measure will be inserted into the anterior superior iliac spine. Measurements will then be taken by sliding the tape measure from proximal to distal until it collapses under the distal end of the medial or lateral malleolus, respectively
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Afyonkarahisar Health Sciences University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Yunus Emre Kundakcı, Asst. Prof., Afyonkarahisar Health Sciences University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 20, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 20, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 5, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 29, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 5, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 7, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 12, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2023/9-387

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings